Pharma BD Deal Intelligence
Organon paid $75M upfront for Forendo Pharma's FOR-6219, a first-in-class oral HSD17B1 inhibitor for endometriosis worth up to $954M, but the Phase 2 ELENA study failed to beat placebo on pelvic pain and Organon discontinued the program in July 2025.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Endometriosis affects approximately 10 percent of women of reproductive age and is one of the most common gynecologic disorders. Treatment options include…
Organon, the women's health pure-play spun off from Merck this summer, has agreed to pay up to $945 million to acquire Finnish biotech Forendo Pharma. The deal…
Organon announced that the Phase 2 ELENA proof-of-concept study evaluating OG-6219 (oral HSD17B1 inhibitor) did not demonstrate improvement in…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Organon acquired Finnish women's health company Forendo Pharma for $75M upfront plus up to $270M in development/regulatory milestones and up to $600M in commercial milestones (~$954M total); the acquisition closed December 13, 2021. The lead asset, FOR-6219 (later OG-6219), was a first-in-class oral HSD17B1 inhibitor intended as a non-hormonal treatment for endometriosis-related pain. On July 2, 2025, Organon disclosed that the Phase 2 ELENA proof-of-concept study did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain versus placebo and announced it plans to discontinue the OG-6219 clinical development program — ending the asset that was the central rationale for the deal (Organon had earlier taken a non-cash impairment on the program). Organon stated it remains committed to its women's health pipeline.
6.5M US cases/yr · $25.0B Global women's reproductive health drug market 2021 (USD MM, IQVIA) · 10 % of reproductive-age women affected by endometriosis
Endometriosis is a chronic estrogen-dependent inflammatory disease in which endometrial-like tissue grows outside the uterus, causing severe pelvic pain, dysmenorrhea, dyspareunia, and infertility. It affects approximately 6.5 million women in the United States (Endometriosis Foundation of America 2021) — roughly 10% of reproductive-age women — with average diagnostic delay of 7-10 years from symptom onset. Standard medical management is symptom-oriented and limited: NSAIDs, combined oral contraceptives, progestins (norethindrone, dienogest), GnRH agonists (leuprolide/Lupron), and the newer oral GnRH antagonists elagolix (Orilissa, AbbVie, FDA approved 2018) and relugolix combination (Myfembree, Myovant/Pfizer, FDA approved Aug 2022 for endometriosis). All current options reduce systemic estrogen, causing menopausal-type side effects (bone loss, vasomotor symptoms) and treatment duration limits. PCOS is the most common endocrine disorder of reproductive-age women, affecting an estimated 5-10 million US women (CDC) with no FDA-approved disease-modifying therapy. The female reproductive health market exceeded $25 billion globally in 2021 (IQVIA). FOR-6219 is a first-in-class oral 17beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor that selectively reduces local intra-tissue estradiol production without lowering systemic estrogen — a mechanistic differentiation that could avoid the menopausal side-effect ceiling of GnRH-class therapies.
Endometriosis competitive set is dominated by hormonal agents that suppress systemic estrogen. Approved/marketed: combined oral contraceptives (multiple manufacturers, mainstay first-line); progestins — norethindrone acetate, dienogest (Visanne, Bayer); medroxyprogesterone (Depo-Provera, Pfizer); GnRH agonists — leuprolide acetate (Lupron Depot, AbbVie); goserelin (Zoladex, AstraZeneca); GnRH antagonists — elagolix (Orilissa, AbbVie/Neurocrine, FDA approved Jul 2018, $80M peak sales annually); relugolix combination (Myfembree, Myovant/Pfizer, FDA approved Aug 2022 endometriosis; uterine fibroids 2021); linzagolix (Yselty, Kissei/ObsEva, EU approved 2022). Late-stage and emerging: ObsEva nolasiban (FSH-receptor modulator, Phase 2/3, terminated); Bayer BAY 3680160 / vilaprisan (selective progesterone receptor modulator, terminated 2018 toxicology); ASKA Pharma dienogest extensions; Forendo's HSD17B1 inhibitor FOR-6219 represented a novel non-systemic estrogen-suppression approach. PCOS landscape: only metformin (off-label), spironolactone (off-label), oral contraceptives, and lifestyle. No FDA-approved PCOS disease-modifying therapy exists. Organon, spun off from Merck in June 2021 as a women's health pure-play, used Forendo to anchor its post-spin pipeline. The deal was terminated as a partnership obligation in 2024 when Organon discontinued FOR-6219 development following a strategic portfolio review.
OG-6219 (formerly FOR-6219), the oral HSD17B1 inhibitor acquired via Forendo, failed to beat placebo on moderate-to-severe endometriosis pelvic pain in the Phase 2 ELENA study. Organon plans to discontinue the OG-6219 clinical development program — the lead asset underpinning the ~$954M deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Organon & Co. / Forendo Pharma (this deal) | 2021 | $954M | — |
| Organon & Co. / Dermavant Sciences Ltd. | 2024 | $1.2B | — |
| Sumitovant Biopharma / Myovant Sciences Ltd. | 2022 | $1.7B | 60 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) | 2015 | $800M | 56 |
| Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA | 2013 | $305M | 16 |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
← Browse all deals · How we score deals
More: 2021 deals · Women's Health deals